RUFY3

RUFY3 is a multifunctional RUN- and FYVE-domain-containing adapter protein that couples small GTPases to cytoskeletal effectors and motor complexes, thereby controlling organelle positioning, cell polarity, and migration in both neuronal and non-neuronal contexts. In neurons, RUFY3 acts as an adapter for Rap2, recruiting the Rac-GEF Tiam2/STEF to lipid-raft domains in axonal growth cones to establish polarity, and it governs caspase-3-dependent axon degeneration through phosphoregulation at S34 (PMID:29089386, PMID:31221560). In non-neuronal cells, RUFY3 functions as an Arl8b effector that bridges Arl8b to the JIP4–dynein–dynactin retrograde motor complex for perinuclear lysosome positioning, and together with HPIP it serves as a noncanonical GEF for Rab5 to drive focal adhesion turnover and integrin trafficking (PMID:35314681, PMID:37797694). An alternative FYVE-domain-bearing isoform preferentially expressed in immune cells mediates endo-lysosome clustering, MHC II antigen presentation, and macrophage migration, while in multiple cancer types RUFY3 promotes epithelial–mesenchymal transition and metastasis through NF-κB and PAK1-dependent pathways (PMID:37463962, PMID:25766321, PMID:34510031).

1. 2007 Medium

   The initial identification of RUFY3 (Singar1) as a brain-enriched RUN-domain protein established its role in suppressing surplus axon formation, revealing that neuronal polarity requires active axon number restriction through a PI3K-dependent mechanism.

   Evidence Overexpression and RNAi knockdown in cultured hippocampal neurons; 2D electrophoresis-based proteomics

   PMID:17439943

   Open questions at the time

   • Mechanism by which RUFY3 restricts axon number downstream of PI3K was undefined
   • No binding partners identified
   • Single lab observation
2. 2014 Medium

   Discovery that RUFY3 physically interacts with the actin-bundling protein Fascin and colocalizes with it in growth cones provided the first direct link between RUFY3 and the actin cytoskeleton, explaining how it controls axon elongation and growth cone morphology.

   Evidence Co-immunoprecipitation, immunofluorescence colocalization, RNAi knockdown and overexpression in mouse hippocampal neurons

   PMID:24720729

   Open questions at the time

   • Whether RUFY3–Fascin interaction is direct or scaffolded was unresolved
   • Structural basis of interaction unknown
3. 2017 High

   Genetic deletion of Rufy3 in mice demonstrated that RUFY3 functions as a Rap2 adapter recruited to lipid raft domains via glycoprotein M6A, where it assembles a ternary complex to recruit the Rac-GEF Tiam2/STEF, thereby establishing the signaling cascade for neuronal polarity.

   Evidence Rufy3 knockout mouse, biochemical fractionation of detergent-resistant membranes, co-immunoprecipitation, immunofluorescence in primary neurons

   PMID:29089386

   Open questions at the time

   • How RUFY3 RUN domain recognizes Rap2-GTP structurally was not determined
   • Whether this Rap2–RUFY3–Tiam2 axis operates outside the nervous system was unknown
4. 2019 High

   RUFY3 was shown to be essential for caspase-3-mediated axon degeneration, and phosphorylation at S34 was identified as a molecular switch: dephosphorylation at S34 is required for degeneration, placing RUFY3 as a gatekeeper between survival and pruning downstream of activated caspases.

   Evidence Rufy3 deletion in vitro and in vivo, mass spectrometry, phosphosite mutagenesis (S34), CASP3 activity assays in TRKA+ sensory neurons

   PMID:31221560

   Open questions at the time

   • Identity of the S34 kinase and phosphatase was not established
   • Whether the degeneration role requires the same Rap2 adapter function is unknown
5. 2015 Medium

   Identification of RUFY3 as a PAK1-interacting partner that drives F-actin-rich protrusive structures and cancer cell migration extended RUFY3 function beyond neurons, establishing its role as a pro-migratory and pro-invasive factor in gastric cancer, later generalized to colorectal and hepatocellular carcinoma through TGF-β1/EMT, FOXK1, and NF-κB pathways.

   Evidence Co-immunoprecipitation, shRNA/siRNA knockdown, overexpression, migration/invasion assays, xenograft and metastasis models across gastric, colorectal, and hepatocellular carcinoma lines

   PMID:25766321 PMID:28089833 PMID:28623323 PMID:34510031

   Open questions at the time

   • Direct phosphorylation of RUFY3 by PAK1 was not demonstrated
   • How RUFY3 activates NF-κB signaling mechanistically is unclear
   • Cancer findings largely from single laboratories per tumor type
6. 2022 High

   A pivotal mechanistic advance showed RUFY3 is an Arl8b effector that directly bridges Arl8b to the JIP4–dynein–dynactin retrograde motor complex, thereby controlling nutrient-dependent perinuclear lysosome positioning and lysosome size, establishing RUFY3 as a central organelle-positioning adapter outside the nervous system.

   Evidence Co-immunoprecipitation, live-cell imaging, siRNA knockdown, pharmacological rescue with PIKFYVE inhibitor, organelle fractionation

   PMID:35314681

   Open questions at the time

   • Structural basis of simultaneous Arl8b and JIP4 engagement was not resolved
   • Whether RUFY3 also promotes anterograde transport via kinesin adaptors was not tested
7. 2023 High

   Characterization of an alternative FYVE-domain-bearing isoform (iRUFY3) in immune cells—upregulated by microbial stimuli and interferons—demonstrated that RUFY3 controls endo-lysosome clustering, MHC II antigen presentation, and macrophage migration, with conditional knockout aggravating bacterial pneumonia, establishing a critical innate immune function.

   Evidence Isoform characterization, PI3P binding assays, siRNA knockdown, phagocyte-specific conditional knockout mice, LPS and bacterial infection models, MHC II presentation and migration assays

   PMID:37463962

   Open questions at the time

   • Whether iRUFY3 engages the same JIP4–dynein module as the neuronal isoform was not directly tested
   • Regulation of isoform switching between FYVE-bearing and FYVE-lacking forms is unknown
8. 2023 High

   The demonstration that RUFY3, together with HPIP, functions as a noncanonical GEF for Rab5 at focal adhesions revealed a new enzymatic activity for RUFY3 and explained how it controls integrin trafficking and focal adhesion turnover during cell migration.

   Evidence In vitro Rab5 GEF activity assay, co-immunoprecipitation, domain deletion mutagenesis of HPIP, siRNA knockdown, focal adhesion turnover and migration assays

   PMID:37797694

   Open questions at the time

   • Whether RUFY3 has intrinsic GEF activity or only potentiates HPIP GEF activity is not fully delineated
   • Structural mechanism of nucleotide exchange is unresolved
9. 2025 Medium

   Identification of a RUFY3–MAP4–CDK1 axis in colorectal cancer, where RUFY3 knockdown induces PANoptosis, added a cell-death-regulatory dimension linking RUFY3 to microtubule-associated and cell-cycle proteins.

   Evidence Co-immunoprecipitation (Rufy3–MAP4, MAP4–CDK1), siRNA knockdown, mouse xenograft model

   PMID:40879686

   Open questions at the time

   • Direct binding between RUFY3 and MAP4 not confirmed with recombinant proteins
   • Whether the PANoptosis phenotype reflects a direct RUFY3 function or an indirect consequence of organelle mispositioning is unclear
   • Single lab, limited mechanistic depth

• Key unresolved questions include the structural basis for RUFY3's simultaneous engagement of multiple small GTPases (Arl8b, Rap2, Rab5, Rap1), how phosphoregulation at S34 intersects with its adapter and GEF functions, and whether the neuronal and immune isoforms share the same JIP4–dynein recruitment mechanism for organelle positioning.
• No high-resolution structure of RUFY3 or any of its complexes
• Relative contributions of GEF vs. adapter functions to cell migration are undefined
• Isoform-specific interactome has not been comprehensively mapped